• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Hyperion to terminate DiaPep277 diabetes program after discovering serious misconduct by Andromeda employees

Hyperion to terminate DiaPep277 diabetes program after discovering serious misconduct by Andromeda employees

September 9, 2014
CenterWatch Staff

Calling it “an unprecedented level of deceit,” Hyperion Therapeutics president and CEO Donald J. Santel told an analyst conference call the company is terminating its DiaPep277 development program for newly diagnosed type 1 diabetes.

Brisbane, Calif.-based Hyperion said it has uncovered evidence certain employees of Andromeda Biotech, which Hyperion acquired in June, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and use the data to manipulate the analyses to obtain a favorable result.

Additional evidence indicates the biostatistics firm and certain Andromeda employees continued the improper practice of sharing and examining un-blinded data from the ongoing DIA-AID 2 trial. All of these acts were concealed from Hyperion and others.

Hyperion has suspended the Andromeda employees known to be involved, is notifying relevant regulatory authorities and continues to explore its legal options. Hyperion said its employees were not involved in any of the improper conduct.

"This new information leaves us with no viable regulatory path forward," said Santel. "We're shocked and disheartened at the serious misconduct and deceit by the implicated Andromeda employees, both before and after the close of our transaction.”

Santel said the company uncovered the deceit while analyzing efficacy results. Andromeda employees had reported excluding 34 blinded patients to arrive at their results. However, when those 34 patients were added back in, “treatment efficacy was lost,” Santel said. Further inquiry revealed those data on the 34 patients had been improperly un-blinded. It was “a coordinated effort to conceal and mislead,” he said.

He told analysts the level of data analysis necessary to uncover the deceit would not been possible before the acquisition was finalized, and that the deception, particularly to regulatory authorities, was “extraordinarily serious.”

“Patients and clinical investigators invested years of their lives in the expectation of an honest result,” Santel said. “We will be engaging with clinical investigators and are prepared to complete the DIA-AID 2 trial because the data may still yield useful insights into the natural history of type 1 diabetes. However, we will not invest further in DiaPep277 beyond completing the DIA-AID 2 trial and meeting our obligations to close out the investigational program as a whole."

The last patient visit in the DIA-AID 2 trial is anticipated to occur in the fourth quarter of 2014. The company expects to record a non-cash impairment charge in the range of $25 million to $55 million.

Hyperion Therapeutics is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. The company's first commercial product, RAVICTI Oral Liquid, was approved in February 2013. 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing